January 16, 2023
The new article “Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study” by Dmitry Shchelokov and Oleg Demin Jr was published in mAbs journal at the end of December 2022.
Oleg Demin Jr comments on the article, “Mechanistic description of biomarkers and endpoints is necessary for accurate analysis of the clinical trial results and prediction of these outcomes by QSP modeling. One of these endpoints is target receptor occupancy which is measured in early clinical trials for therapeutic antibodies including monoclonal and bispecific ones, etc. In the published article we have shown that the method of target occupancy measurement can affect the results of clinical trials and their interpretation”.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Edinburgh, UK (INSYSBIO UK LIMITED), Limassol, Cyprus (INSYSBIO CY Ltd) and Moscow, Russia (INSYSBIO LLC). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | August 2023 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
| |
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
|
14
|
15
|
16
1.
16 Aug 2023 16:51
InSysBio to participate in World Bispecific Summit 2023
InSysBio announces its participation in the 14th Annual World Bispecific Summit which is to be held on October 2-4, 2023 at Boston Park Plaza, Boston, MA. Oleg Demin Jr, Scientific Director, QSP modeling in Oncology & Immuno-Oncology, InSysBio will give a talk within its frames
|
17
|
18
|
19
|
20
|
|
21
|
22
|
23
|
24
|
25
|
26
|
27
|
|
28
|
29
|
30
|
31
| |||
Thank you for your message! We will get back to you shortly.
